MedTrace Logo

Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma

NCT00535314 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-05-31

No results posted yet for this study

Summary

The primary purpose of the study is to determine the proportion of patients without progression at 6-months in patients with unresectable Stage III or Stage IV melanoma who are taking RTA 402.

Conditions

  • Malignant Melanoma

Interventions

DRUG

RTA 402 Dose1

DRUG

RTA 402 Dose2

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00535314 on ClinicalTrials.gov